GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Capex-to-Revenue

Financiere de Tubize (XBRU:TUB) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 1985. Start your Free Trial

What is Financiere de Tubize Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Financiere de Tubize's Capital Expenditure for the six months ended in Dec. 2023 was €0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was €0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Financiere de Tubize Capex-to-Revenue Historical Data

The historical data trend for Financiere de Tubize's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Capex-to-Revenue Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Financiere de Tubize's Capex-to-Revenue

For the Biotechnology subindustry, Financiere de Tubize's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Financiere de Tubize's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Financiere de Tubize's Capex-to-Revenue falls into.



Financiere de Tubize Capex-to-Revenue Calculation

Financiere de Tubize's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Financiere de Tubize's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize  (XBRU:TUB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Financiere de Tubize Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (XBRU:TUB) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (XBRU:TUB) Headlines

No Headlines